Background Chimeric antigen receptor T cell (CAR-T)-based immunotherapies have reshaped the therapeutic landscape of cancer treatment. in particular for patients afflicted with leukemia. However. defects in CAR behaviors and clinical complications have hindered their widespread application across diverse cancer types. https://www.jalyttlers.shop/product-category/purse/